Last reviewed · How we verify

NCT05506215: DFUs

Randomized Clinical Study Comparing SynPath to Standard of Care in Treatment of Chronic Diabetic Foot Ulcers

Terminated NA Last updated 5 March 2024
What this trial tests

NA trial testing SynPath Acellular Dermal Matrix plus Off-loading Device in Diabetic Foot in 25 participants. Terminated before completion.

Timeline
10 July 2022
Primary endpoint
26 February 2024
26 February 2024

Quick facts

Lead sponsorPolyNovo Biomaterials Pty Ltd.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment25
Start date10 July 2022
Primary completion26 February 2024
Estimated completion26 February 2024
Sites7 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

PolyNovo Biomaterials Pty Ltd.

Who can join

18 and older, any sex, with Diabetic Foot or Chronic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will evaluate the efficacy of SynPath™, a synthetic dermal matrix, in the treatment of diabetic foot ulcers in subjects with diabetes mellitus versus Standard of Care treatment. Half the subjects with be treated using SynPath™ while the other half will receive Standard of Care treatment

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Foot

Currently open trials in the same condition.

Other PolyNovo Biomaterials Pty Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05506215.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing